Cochlear is a leading manufacturer of cochlear implant devices, holding approximately 60% of the global market share. The company specializes in developing implantable hearing solutions that significantly improve the quality of life for individuals with hearing loss. Its primary products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In developed markets, where cochlear implants are considered the standard care for children with severe to profound hearing loss, the company generates around 80% of its revenue. Additionally, Cochlear targets the growing population of seniors with hearing challenges in these markets. Revenue distribution in fiscal 2020 showed that 49% came from the Americas, 35% from Europe, the Middle East, and Africa, and 16% from the Asia-Pacific region. Overall, Cochlear is committed to transforming the understanding and treatment of hearing loss.
Oticon Medical offers bone anchored hearing systems and cochlear implant solutions.
Seer
Series A in 2021
Seer is a medical technology company based in Melbourne, Victoria, focused on the diagnosis and management of neurological conditions, particularly epilepsy. Founded in 2016, Seer develops wearable devices integrated with cloud computing technology that enables hospital-standard monitoring and diagnosis in a home setting. The application not only tracks epilepsy but also monitors cardiac diseases and sleep patterns, capturing medical events through a mobile device. By utilizing machine learning systems, Seer provides patients with personalized insights, predictions, and alerts, helping them understand long-term illness patterns and enhancing their overall healthcare experience.
Nyxoah
Corporate Round in 2020
Nyxoah S.A. is a health-technology company based in Mont-Saint-Guibert, Belgium, established in 2009. The company specializes in developing and commercializing innovative solutions for treating sleep disordered breathing conditions, particularly moderate to severe obstructive sleep apnea (OSA). Its primary product, the Genio system, is a user-centered, bilateral neurostimulation therapy that has received CE-Mark validation. OSA is a prevalent condition linked to significant health risks, including increased mortality and various comorbidities such as cardiovascular diseases, depression, and stroke. Nyxoah aims to address these critical health challenges through its advanced therapeutic offerings.
Nyxoah
Series C in 2018
Nyxoah S.A. is a health-technology company based in Mont-Saint-Guibert, Belgium, established in 2009. The company specializes in developing and commercializing innovative solutions for treating sleep disordered breathing conditions, particularly moderate to severe obstructive sleep apnea (OSA). Its primary product, the Genio system, is a user-centered, bilateral neurostimulation therapy that has received CE-Mark validation. OSA is a prevalent condition linked to significant health risks, including increased mortality and various comorbidities such as cardiovascular diseases, depression, and stroke. Nyxoah aims to address these critical health challenges through its advanced therapeutic offerings.
EarLens
Series C in 2017
Earlens is a medical technology company focused on improving the hearing experience for individuals with hearing loss. It has created the Earlens Contact Hearing Solution, a unique device that directly stimulates the eardrum using a small lens, replicating the natural hearing process. Unlike conventional hearing aids that amplify sound, the Earlens solution delivers sound directly to the eardrum, providing superior sound quality and a broader bandwidth. This innovative, non-surgical approach allows for automatic adjustments in challenging listening environments while minimizing feedback. The technology received FDA clearance in 2019 for its second generation, marking a significant advancement in hearing solutions aimed at enhancing the quality of life for those with hearing impairment.
Sycle
Acquisition in 2017
Sycle is an audiology practice management software company that provides a cloud-based platform designed for hearing care clinics. The software integrates various services, including patient clinical data management, financing, reimbursement, and marketing campaigns, as well as front and back office operations. This comprehensive solution allows audiologists to focus more on patient care while reducing administrative tasks, thereby enhancing operational efficiency within hearing care practices.
EarLens
Series C in 2016
Earlens is a medical technology company focused on improving the hearing experience for individuals with hearing loss. It has created the Earlens Contact Hearing Solution, a unique device that directly stimulates the eardrum using a small lens, replicating the natural hearing process. Unlike conventional hearing aids that amplify sound, the Earlens solution delivers sound directly to the eardrum, providing superior sound quality and a broader bandwidth. This innovative, non-surgical approach allows for automatic adjustments in challenging listening environments while minimizing feedback. The technology received FDA clearance in 2019 for its second generation, marking a significant advancement in hearing solutions aimed at enhancing the quality of life for those with hearing impairment.
Otologics
Acquisition in 2009
Otologics, LLC, a medical device company, develops and manufactures amplification products that are designed to improve communication of life for individuals with hearing loss. It offers Carina, an implantable treatment option for hearing loss. The company was founded in 1996 and is headquartered in Boulder, Colorado.
Cochlear Bone Anchored Solutions
Acquisition in 2005
Cochlear Bone Anchored Solutions manufactures, and sells medical systems for hearing and facial rehabilitation.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.